uniQure NV
(NASDAQ : QURE)

( )
QURE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.39%295.001.4%$597.51m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
-1.17%66.841.0%$365.49m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%372.162.6%$302.06m
VRTXVertex Pharmaceuticals, Inc.
-0.25%220.001.9%$274.45m
CLVSClovis Oncology, Inc.
1.12%13.5814.7%$244.55m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-1.32%67.3211.4%$205.58m
ALXNAlexion Pharmaceuticals, Inc.
0.59%113.132.0%$203.97m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
28.87%129.4814.6%$150.64m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BLUEbluebird bio, Inc.
2.55%86.1914.2%$140.23m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.